Vaelis@Vaelis_X
Every humanoid robot being built right now depends on a $88M Japanese company that almost nobody in Western markets has looked at.
While capital is flooding into robot software, AI brains, and system integrators, everyone is ignoring the one company that decides whether robotic joints actually function. And that oversight is the opportunity.
The name is $6464.T — Tsubaki Nakashima Co., Ltd.
Tesla Optimus requires 14 to 16 planetary roller screws per unit to actuate its limbs. Each screw is only as precise as the rolling elements housed inside it. Sub-micron Silicon Nitride ceramic balls and specialty steel rollers are the foundational material the entire physical AI execution layer runs on.
Tsubaki Nakashima is the dominant global supplier of those elements.
They supply SKF, Schaeffler, NSK, and Timken without competing with any of them. That neutral upstream position makes them the one indispensable node in the entire advanced motion industry. Every major bearing manufacturer on earth is their customer. Their proprietary in-house grinding and sintering equipment ensures no competitor can replicate their yield at scale.
The Si3N4 precision ceramic ball market grows from $267M in 2025 to $612M by 2032 at a 12.54% CAGR. Their engineered plastics division, TN Plastics, adds another layer: a collaboration with a major robotics manufacturer achieved a 20% reduction in robot weight and a 1.3x improvement in operational speed by replacing steel elements with precision polymer components. In February 2026, TN Plastics launched microfluidic plate manufacturing, entering a medical diagnostics market projected to grow from $40B to $75B by 2030.
Now the financials, because this is where most investors got it completely wrong:
The company reported a ¥27.21B GAAP net loss in FY2025. Screeners flagged it as distressed. Most investors stopped reading there.
What they missed:
¥16.7B was non-cash goodwill impairment. ¥6.4B was a non-cash inventory write-down on legacy steel stock. ¥2.9B was a deferred tax adjustment. None of it touched the cash account.
Actual FY2025 cash generation: Operating Cash Flow ¥10.52B. Free Cash Flow ¥11.64B — an all-time company record.
Q1 2026 confirmed the full return to GAAP profitability:
Operating Profit: ¥1.13B (up 214.6% YoY)
Net Profit: ¥308M (vs. a net loss of ¥559M in Q1 2025)
EBITDA: ¥2.00B (up 62.1% YoY)
The CEO executing this is Itaru Matsuyama — BCG, DuPont Electronic Materials, KKR Capstone. Appointed July 2024 with one mandate: private-equity-style transformation. He has divested the entire ball screw division to MinebeaMitsumi, closed plants in the Netherlands, Korea, and Tennessee, and suspended all dividends to direct 100% of cash toward debt reduction.
The valuation:
Tsubaki Nakashima trades at 0.31x to 0.34x Price-to-Book and 0.17x Price-to-Sales.
Harmonic Drive Systems, supplying reducers for the same robotic joints, trades at 4.23x P/B and 10.24x P/S.
A re-rating to just 0.8x P/S — still a massive discount to every robotics peer — implies 470% upside from current levels.
The risks, because a real thesis requires them:
European auto stagnation drove a 2.7% revenue decline in Q1 2026. Net debt sits at ¥58.2B. Tariff exposure is real across global facilities.
Mitigations: Indian manufacturing expansion and TN Plastics medical microfluidics buffer the auto cyclicality. The ¥20B in subordinated debt is rated BBB Stable by R&I and doesn't mature until 2051. A Local for Local manufacturing model with US plants in Michigan and Georgia neutralizes tariff risk by supplying American customers from domestic, tariff-exempt soil.
The market is pricing this as a failing cyclical auto supplier.
What it actually is: the material science chokepoint of the entire physical AI supply chain, run by a KKR-trained CEO generating record cash and trading at a fraction of liquidation value.
A $88M company sitting underneath the entire humanoid robotics buildout.
NFA. Do your own due diligence.
